News >

Gainor Highlights Future of Immunotherapy in Stage III Lung Cancer Treatment

Ellie Leick
Published: Sunday, Jul 14, 2019

Justin F. Gainor, MD

Justin F. Gainor, MD
The PACIFIC-2 study (NCT03519971) is examining the use and placement of immunotherapy in the treatment of patients with unresectable locally advanced lung cancer, specifically whether it would be most appropriately delivered after chemoradiation or concurrently, explained Justin F. Gainor, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x